Compass Therapeutics, Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, has announced a significant milestone in its ongoing development of antibody-based therapeutics aimed at treating a variety of human diseases. The company reported that the first patient has been dosed in a Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody for patients with solid tumors.
Earlier this year, Compass Therapeutics publicized the launching of the first-in-human clinical trial of CTX-8371 after publishing preclinical data in the journal OncoImmunology. The company’s research article “A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity,” highlighted the unique mechanism-of-action of CTX-8371, showing its potential to dual blockade of PD-1 and PDL-1 and induce cleavage of cell surface PD-1.
The peer-reviewed article further demonstrated the drug’s enhanced antitumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in vitro and in vivo experimental environments. According to the provided data, this next generation checkpoint blocker exhibits greater anti-tumor activity, showing promising results that led to the initiation of the current Phase 1 clinical trial.
After the initiation of the clinical trial in April 2024, Compass Therapeutics continues to make strides in advancing the development of proprietary antibody-based therapeutics for multiple human diseases. The dosing of the first patient represents an important step for the company in exploring the efficacy and potential of the drug in treating solid tumors.
In summary, Compass Therapeutics is propelling forward in the development and clinical testing of CTX-8371. This PD-1 x PD-L1 bispecific antibody, showcasing enhanced anti-tumor activity, is a promising therapeutic strategy for patients with solid tumors. With the first dose administered successfully, the Phase 1 clinical trial is well underway, signaling a significant advance in the treatment landscape for oncology.
Comments